Article
The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping.
Pharmacogenetics and genomics - 1 Aug 2014
Langaee Taimour Y, Zhu Hao-Jie, Wang Xinwen, El Rouby Nihal, Markowitz John S, Goldstein Joyce A, Johnson Julie A
Abstract excerpt
BACKGROUND/OBJECTIVES: The polymorphic hepatic enzyme CYP2C19 catalyzes the metabolism of clinically important drugs such as clopidogrel, proton-pump inhibitors, and others and clinical pharmacogenetic testing for clopidogrel is increasingly common. The CYP2C19*10 single-nucleotide polymorphism (SNP) is located 1 bp upstream the CYP2C19*2 SNP. Despite the low frequency of the CYP2C19*10 allele, its impact on...
Topics
Join the communities discussing this publication.